Abstract: The invention relates to a method of treating rheumatoid arthritis in a patient comprising the steps of: a) providing a biological sample from a patient, b) measuring the level of soluble VE-cadherin in the biological sample obtained at step a); c) comparing said level of soluble VE-cadherin with a predetermined reference value, and if the level of soluble VE-cadherin measured at step b) is higher that the predetermined reference value, treating the patient until a basal level of soluble VE-cadherin is reached.

Abstract: Compounds having a core comprised of an aromatic ring and at least two annulated beta-substituted fused thiophene ring systems of the general formula: -(?-R2—FT2ArFT2-?-R2)—, and polymers or copolymers thereof, of the general formulas: -{-(?-R2—FT2ArFT2-?-R2)-G1-}n-, or -{-G1-(?-R2—FT2ArFT2-?-R2)-G1-G2-}n-, where ?-R2—FT2ArFT2-?-R2, -G1-, -G2-, and n are as defined herein. Also disclosed are compositions, articles, or devices comprising the polymers, and methods for making and using the polymers. The compositions, articles, or devices can be used, for example, for electronic applications, such as light emitting devices and semiconductor devices.

Abstract: The disclosure relates to methods for determining mixedness of batch material for making ceramic ware, and methods for obtaining substantially consistent mixedness of batch material for making ceramic ware.

Abstract: Compounds having a core comprised of an aromatic ring and at least two annulated beta-substituted fused thiophene ring systems of the general formula: -(?-R2—FT2ArFT2-?-R2)—, and polymers or copolymers thereof, of the general formulas: -{-(?-R2—FT2ArFT2-?-R2)-G1-}n-, or -{-G1-(?-R2—FT2ArFT2-?-R2)-G1-G2-}n-, where ?-R2—FT2ArFT2-?-R2, -G1-, -G2-, and n are as defined herein. Also disclosed are compositions, articles, or devices comprising the polymers, and methods for making and using the polymers. The compositions, articles, or devices can be used, for example, for electronic applications, such as light emitting devices and semiconductor devices.

Abstract: A method of treating a patient with Parkinson's disease is provided. The method comprises orally administering to the patient a first agent comprising levodopa and once-daily, orally administering to the patient a second agent comprising amantadine, or a pharmaceutically acceptable salt thereof. The amount of levodopa administered is reduced by 20% to 80% of the amount required in the absence of amantadine.

Abstract: Compositions and methods for administering memantine to a subject are provided. In particular, a solid pharmaceutical composition in a unit dosage form for once daily oral administration is provided. The compositions comprises an extended release formulation of 22.5 mg to 33.75 mg memantine, or a pharmaceutically acceptable salt thereof, wherein administration of a dose of the composition to a human subject provides a mean plasma memantine concentration profile characterized by a change in memantine concentration as a function of time (dC/dT) that is less than 50% of the dC/dT provided by the same quantity of an immediate release form of memantine, determined in a time period between 0 hours to 6 hours after administration of memantine, and wherein dC/dT is measured in a single-dose human PK study. Methods of treating dementia, in particular Alzheimer's diseases, using the compositions are provided.

Abstract: The invention provides compositions comprising extended release memantine in combination with immediate release donepezil to a subject. Memantine in an extended release form containing 22.5 to 30 mg memantine or a pharmaceutically acceptable salt thereof in combination with donepezil achieves particular pharmacokinetic criteria such as change in plasma concentration of memantine over time and ratio of maximum memantine plasma concentration to mean memantine plasma concentration.

Abstract: Compounds having a core comprised of an aromatic ring and at least two annulated beta-substituted fused thiophene ring systems of the general formula: -(?-R2—FT2ArFT2-?-R2)—, and polymers or copolymers thereof, of the general formulas: -{-?-R2—FT2ArFT2-?-R2)-G1-}n-, or -{-G1-(?-R2—FT2ArFT2-?-R2)-G1-G2-}n-, where ?-R2—FT2ArFT2-?-R2, -G1-, -G2-, and n are as defined herein. Also disclosed are compositions, articles, or devices comprising the polymers, and methods for making and using the polymers. The compositions, articles, or devices can be used, for example, for electronic applications, such as light emitting devices and semiconductor devices.

Abstract: A compositional range of high strain point and/or intermediate expansion coefficient alkali metal free aluminosilicate and boroaluminosilicate glasses are described herein. The glasses can be used as substrates or superstrates for photovoltaic devices, for example, thin film photovoltaic devices such as CdTe or CIGS photovoltaic devices or crystalline silicon wafer devices. These glasses can be characterized as having strain points ?600° C., thermal expansion coefficient of from 35 to 50×10?7/° C.

Abstract: The disclosure relates to methods for determining mixedness of batch material for making ceramic ware, and methods for obtaining substantially consistent mixedness of batch material for making ceramic ware.

Abstract: Compounds having a core comprised of an aromatic ring and at least two annulated beta-substituted fused thiophene ring systems of the general formula: -(?-R2-FT2ArFT2-?-R2)-, and polymers or copolymers thereof, of the general formulas: -{-?-R2-FT2ArFT2-?-R2)-G1-}n-, or -{-G1-(?-R2-FT2ArFT2-?-R2)-G1-G2-}n-, where ?-R2-FT2ArFT2-?-R2, -G1-, -G2-, and n are as defined herein. Also disclosed are compositions, articles, or devices comprising the polymers, and methods for making and using the polymers. The compositions, articles, or devices can be used, for example, for electronic applications, such as light emitting devices and semiconductor devices.

Abstract: Robust testing method for combinations of cars and child restraints for the protection of children in vehicles.

Abstract: A system and method for providing an improved data schema for representing financial transactions using data relationships based on financial transaction information is provided. Instead of relying on financial transaction documents for financial transaction information, the underlying data and their relationships are used to represent the financial transaction information. For example, each entity involved in a financial transaction may be represented separately. Furthermore, each entity may be associated with a role played by the entity in the financial transaction and entity type that describes the type of entity. Relationships in which the entity may be involved may depend upon this and other information.

Abstract: The invention is related to the identification of CSA binding domains in var2CSA homologs from different parasite strains and furthermore to an isolated polypeptide comprising a CSA-binding domain sequence substantially as shown in SEQ ID NO:1, or functional equivalent thereof, or the corresponding portion of PfEMP1 from a strain of Plasmodium, substantially in isolation from sequences naturally occurring adjacent thereto in the PfEMP1 protein, and related nucleotide sequences, vectors, host cells, vaccines, and methods of use.

Abstract: The invention relates to the use of tick cement proteins in the production of vaccines for protecting animals against the bite of blood-sucking ectoparasites and against the transmission of viruses, bacteria and other pathogens by such ectoparasites. When used as vaccine components, the tick cement proteins of the invention confer broad cross-reactivity against a variety of species of ectoparasite.

Abstract: A fabric softening composition comprises a cationic fabric softening compound comprising 2 or more long hydrocarbyl chains, an oil comprising from 8 to 40 carbon atoms, a nonionic stabiliser comprising a nonionic alkoxylate having an average alkoxylation number of from 10 to 40 wherein the composition is in the form of a macroemulsion. A method for softening fabrics comprises adding the fabric softening composition to a laundry operation.

Abstract: The present invention provides a method of producing an animal embryo, the method comprising transferring from a nuclear donor cell which has been selected on the basis that it is histone hypomethylated at least a portion of the nuclear contents including at least the minimum chromosomal material able to support development into a suitable recipient cell.

Abstract: Disclosed are pharmaceutical compositions of an integrin ?v?3 receptor antagonist containing mannitol as the binding agent. The compositions are prepared by wet granulation or direct compression tablet formulation. These pharmaceutical formulations are useful for inhibiting bone resorption associated with osteoporosis, metastatic bone disease, hypercalcemia of malignancy, and Paget's disease.

Abstract: The present invention relates to the use of a protein termed 64p in the production of vaccines for protecting animals against the bite of blood-sucking ectoparasites and against the transmission of viruses, bacteria and other pathogens by such ectoparasites.

Abstract: A fabric softening composition comprises a cationic fabric softening compound comprising 2 or more long hydrocarbyl chains, an oil comprising from 8 to 40 carbon atoms, a nonionic stabiliser comprising a nonionic alkoxylate having an average alkoxylation number of from 10 to 40 wherein the composition is in the form of a macroemulsion. A method for softening fabrics comprises adding the fabric softening composition to a laundry operation.